1248 Management’s AstraZeneca AZN Stock Holding History

1248 Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$564K	Hold	2,976	–	–	0.22%	62
2026 Q1	$587K	Buy	2,976 +2,915	+4,779%	+$562K	0.27%	54
2025 Q4	$11.2K	Hold	61	–	–	0.01%	143
2025 Q3	$9.36K	Hold	61	–	–	0.01%	144
2025 Q2	$8.53K	Buy	61 +26	+74%	+$3.64K	﹤0.01%	159
2025 Q1	$5.14K	Buy	+35	New	+$5.06K	﹤0.01%	167

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

1248 Management's AZN Position: Q2 2026 in Review

1248 Management held its AstraZeneca (AZN) position steady in Q2 2026 at 2,976 shares worth $564K. The position accounts for 0.22% of the portfolio, ranked #62.

1248 Management first reported a position in AZN in Q1 2025 and has held it in 6 quarters since. The position peaked at $587K in Q1 2026. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

1248 Management held 2,976 shares of AstraZeneca worth $564K as of Q2 2026.
1248 Management left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.22% of 1248 Management's portfolio in Q2 2026, its #62 holding.
1248 Management first reported a position in AstraZeneca in Q1 2025 and has held it in 6 quarters since.
1248 Management's AstraZeneca position peaked at $587K in Q1 2026.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on 1248 Management's 13F filing for Q2 2026, filed 13 Aug 2026.